Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer

This study found that while ARPIs are standard of care for advanced prostate cancer, metabolic abnormalities were frequently documented shortly after initiation of concurrent ADT and ARPI therapy. This suggests that monitoring should extend beyond cancer-specific outcomes to include early detection of metabolic dysfunction, ideally through multidisciplinary care. The early burden of metabolic abnormalities highlights the need to evaluate scalable interventions addressing cardiometabolic risk in men with prostate cancer.

Corresponding Authors: Grace Lu-Yao, PhD (grace.luyao@jefferson.edu), and Amy L. Shaver, PhD, PharmD, MPH (amy.shaver@jefferson.edu), Department of Medical Oncology and Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College, Sidney Kimmel Comprehensive Cancer Center at Jefferson, 1101 Market St, Philadelphia, PA 19107.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.